Search

Displaying results 4071 - 4080 of 7284 in total
  1. Drug

    Relutrigine

    go.drugbank.com/drugs/DB21614
    Investigational

    Relutrigine has a monoisotopic molecular weight of 407.08 Da. … Relutrigine is a small molecule drug. The usage of the INN stem '-trigine' in the name indicates that Relutrigine is a sodium channel blocker, signal transduction modulator.

  2. Drug

    Foselutoclax

    go.drugbank.com/drugs/DB21663
    Investigational

    Foselutoclax has a monoisotopic molecular weight of 1158.28 Da. … Foselutoclax is a small molecule drug. The usage of the INN stem '-toclax' in the name indicates that Foselutoclax is a B-cell lymphoma 2 (Bcl-2) inhibitor.

  3. Drug

    Poliovirus type 2 antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB10796
    ApprovedInvestigational

    The vaccine contains purified and inactivated poliovirus type 2 that were grown from a continuous line of monkey kidney cells. … Poliovirus type 2 antigen is a suspension of poliovirus Type 2 (MEF-1) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis

    Mixtures: Dt Polio Adsorbed - Sus Im
  4. Drug

    Eprodisate

    go.drugbank.com/drugs/DB06405
    Investigational

    Eprodisate slows the decline of renal function in AA amyloidosis.

  5. Drug

    Pindolol

    go.drugbank.com/drugs/DB00960
    ApprovedInvestigational

    [A231064] Pindolol was granted FDA approval on 3 September 1982.[L32348] … Pindolol is a first generation non-selective beta blocker used in the treatment of hypertension.

  6. Drug

    Carglumic acid

    go.drugbank.com/drugs/DB06775
    ApprovedInvestigational

    Carglumic acid is a drug used for the treatment of hyperammonemia in patients with a deficiency in N-acetyl glutamate synthase. … Food and Drug Administration (FDA) on 18 March 2010.

  7. Drug

    Ganirelix

    go.drugbank.com/drugs/DB06785
    ApprovedInvestigational

    Ganirelix is a synthetic decapeptide and a competitive gonadotropin-releasing hormone (GnRH) antagonist. Derived from endogenous GnRH, ganirelix has amino acid substitutions. … [A252195] Ganirelix was first approved by the FDA on July 29, 1999.[L43070]

  8. Drug

    Maraviroc

    go.drugbank.com/drugs/DB04835
    ApprovedInvestigational

    It was approved for use by the FDA in August, 2007. … Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the

  9. Drug

    Ezogabine

    go.drugbank.com/drugs/DB04953
    ApprovedWithdrawn

    FDA approved in June 10, 2011 under the name of ezogabine. … It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures

  10. Drug

    Perampanel

    go.drugbank.com/drugs/DB08883
    ApprovedInvestigational

    Perampanel is a noncompetitive AMPA glutamate receptor antagonist. … The FDA label includes an important black-boxed warning of serious or life-threatening behavioral and psychiatric reactions in patients taking Fycompa™.